Use of 5-alpha-reductase inhibitors (5-ARIs) by men on active surveillance (AS) for prostate cancer is associated with a lower likelihood of definitive treatment and pathologic progression

Use of 5-alpha-reductase inhibitors (5-ARIs) by men on active surveillance (AS) for prostate cancer is associated with a lower likelihood of definitive treatment and pathologic progression

https://www.renalandurologynews.com/home/news/urology/prostate-cancer/5-alpha-reductase-inhibitors-aid-prostate-cancer-active-surveillance-patients/?utm_source=social&utm_medium=facebook&utm_content=ccf50483-31ed-4a19-8575-6c7185759cef&utm_campaign=run_daily_posts